Does DC Medicaid Cover Wegovy or Zepbound? Fee-for-Service and Both Plans Compared

No. DC Medicaid does not pay for Wegovy, Zepbound or other GLP-1s prescribed for weight loss: the District’s fee-for-service drug list excludes anti-obesity drugs, and both managed care plans rule out weight loss as a covered use.^[1][3][4] As of November 2026 the two plans, AmeriHealth Caritas DC and MedStar Family Choice DC, do cover Wegovy for heart-risk reduction or the liver disease MASH and Zepbound for sleep apnea with prior authorization, on tests that differ between them.^[3][4]

Can DC Medicaid pay for a GLP-1 prescribed to lose weight?

No, on any of the three rulebooks. The fee-for-service preferred drug list, effective September 18, 2026, names anti-obesity drugs among its excluded classes.^[1] AmeriHealth Caritas DC’s policy is titled for non-weight-loss uses and lists a weight-loss diagnosis as an exclusion.^[3] MedStar Family Choice DC says Zepbound cannot be approved for weight management and limits Wegovy to two other uses.^[4] Under federal law, states and the District may leave weight-loss drugs out of Medicaid, so this is a local choice.^[9]

Which DC Medicaid rules apply to you?

That depends on how you get your benefits. People in fee-for-service Medicaid follow the District’s drug list, run by Prime Therapeutics.^[1] People in DC Healthy Families follow their plan’s formulary. Since August 1, 2026 there have been two plans: Wellpoint DC members were moved to AmeriHealth Caritas DC that day, and they can switch to MedStar Family Choice DC until January 31, 2027.^[2] The District’s notice says benefits stay the same whichever plan you choose, but the drug criteria the two plans publish are not identical.^[2][3][4]

The fee-for-service list carries no Wegovy or Zepbound entry or criteria for heart disease or sleep apnea.^[1] A fee-for-service member with one of those conditions should have the prescriber ask the pharmacy program directly how such a request is handled.

How do the two DC Healthy Families plans compare?

Three differences matter most. AmeriHealth’s heart route starts at age 45 and turns away anyone with diabetes, while MedStar’s starts at 18 but needs a cardiologist.^[3][4] Zepbound’s label covers moderate to severe sleep apnea in adults with obesity.^[11] AmeriHealth accepts a sleep apnea request from someone who could not use PAP, while MedStar does not mention PAP but excludes people with diabetes.^[3][4] And at renewal, AmeriHealth asks sleep apnea patients to show a 5% weight loss, while MedStar requires a repeat sleep study once treatment passes 12 months and refuses renewal if BMI has fallen below 30.^[3][4]

Those last two rules can collide with success: a person who loses enough weight on Zepbound to drop under a BMI of 30 loses MedStar coverage at renewal.^[4] For Wegovy, MedStar refuses renewal at a BMI of 24 or below.^[4] Our guides to Zepbound for sleep apnea and GLP-1s and MASH cover what the trials behind these uses showed.

Both plans list a fallback when criteria are not met. AmeriHealth sends such requests to a medical director or clinical reviewer for medical necessity review, and MedStar runs a medical exception process by phone at 855-798-4244.^[3][5] MedStar’s formulary lists Wegovy and Zepbound for ages 18 and up, with the lower titration strengths limited to four pens a year.^[5]

Does DC Medicaid cover Ozempic and Mounjaro for diabetes?

Yes. On the fee-for-service list, generic liraglutide, the Ozempic injection and Trulicity are preferred, while Mounjaro, Ozempic tablets, Rybelsus and Victoza are non-preferred and need prior authorization.^[1] MedStar’s diabetes form is stricter. It asks for type 2 diabetes with an A1c of at least 7.5%, or heart disease plus a BMI of 27 or more and an A1c of 6.5% or more, plus three-month trials of two other diabetes drugs and of liraglutide before Mounjaro, Ozempic or Trulicity.^[6] None of these is covered for weight loss.

What about children and teens?

Wegovy’s label includes obesity treatment from age 12, but neither plan covers weight loss, and MedStar lists both drugs for adults only.^[10][5] Federal law requires Medicaid to provide necessary treatment found through child health screening for people under 21, even when the plan of benefits leaves it out.^[12] We found no DC document that applies that rule to GLP-1s. A family can ask in writing for a medical necessity review under EPSDT, the federal child-health benefit, by name.

How do you appeal a denial in DC?

• Requests. MedStar takes GLP-1 requests by fax at 202-243-6258 and must decide within 24 hours, so send complete records the first time.^[6][5]
• Plan appeal. Managed care members have 60 calendar days from the date on the denial notice to appeal to the plan.^[7]
• Fair hearing. If the plan upholds the denial, federal rules give at least 90 and at most 120 days from the plan’s decision notice to request a fair hearing. The notice states the exact window.^[8]

An appeal has the most to work with when the dispute is over a covered use, such as whether a stent counts as established heart disease or whether a sleep study is recent enough. Our walkthrough of prior authorization and appeals covers what to send, and the state Medicaid GLP-1 checker compares other states.

What are the options without coverage?

Paying cash is the main one. Lilly’s savings card for insured patients excludes Medicaid enrollees.^[13] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s self-pay Zepbound.^[13][14] Read each offer’s terms on government-program enrollment first. Our list of the cheapest GLP-1 routes without insurance compares them.